Sparsentan Versus Irbesartan in Pediatric Patients With FSGS
Kidney International Reports – 2026
Search Results
Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Resource type
Resource type
×Filter by:
Information type
Information type
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Study type
Study type
×Sort by
Publications
Results57
Review of the Clinical, Humanistic, and Economic Burden of Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Prevalence, Resource Utilization, and Economic Impact of Kidney Function and Proteinuria in Patients With Focal Segmental Glomerulosclerosis
The American Journal of Managed Care – 2026
Targeting Endothelin and Angiotensin Pathways for Kidney Function Preservation in Glomerular Disease
European Medical Journal – 2026
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Clinical Journal of the American Society of Nephrology – 2025
Lived Experiences of Patients and Care Providers in Focal Segmental Glomerular Sclerosis and IgA Nephropathy
Glomerular Diseases – 2025
Congress materials
Results167
Spatial transcriptomics reveals sparsentan-associated remodelling of complement-active renal niches in IgAN
2026
The effect of Sparsentan on urine and plasma proteome of patients with IgAN– Findings from the SPARTAN study
2026
Natural History of Recurrent IgA Nephropathy after Kidney Transplantation: Findings from the UK National Registry of Rare Kidney Diseases (RaDaR)
2026
Urinary Biomarker Data From the PROTECT Study in IgA Nephropathy Demonstrate Renal Anti-Inflammatory Actions of Sparsentan, Including Reduced Macrophage, Complement, and B-Cell Activation Signals
2026
Urinary biomarker data fromthe PROTECT study in IgAnephropathy demonstrate renalanti-inflammatory actions of sparsentan, including reduced macrophage, complement, and B-cell activation signals
2026
The Association between Achievement of Low Proteinuria Thresholds and Health-Related Quality ofLife in Focal Segmental Glomerulosclerosis: Pooled DUET & DUPLEX Analysis
2026
Events
Results15
Past
October 21–25, 2026 – Denver, CO
American Society of Nephrology (ASN) Kidney Week 2026
Past
June 3–6, 2026 – Glasgow, Scotland
63rd European Renal Association (ERA) Congress 2026
Past
June 23, 2026 – Chicago, IL
Path 2 Progress: Chicago
Past
May 6–10, 2026 – New Orleans, LA
National Kidney Foundation (NKF) Spring Clinical Meetings 2026
Past
April 24–27, 2026 – Boston, MA
97th Pediatric Academic Societies (PAS) Meeting 2026
Past
April 25–28, 2026 – New Orleans, LA
American Nephrology Nurses Association (ANNA) National Symposium 2026
Abstracts
Results48
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Concomitant Sparsentan and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2is) in Patients With IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)
Sparsentan as First-Line Treatment of Incident Patients With IgA Nephropathy: Preliminary Findings From the SPARTAN Trial
Sparsentan Receptor Occupancy Modeling, Clinical Actions, and Safety Visual Abstract
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan (SPAR) vs Irbesartan (IRB) in Patients (Pts) With Immunoglobulin A Nephropathy (IgAN)
Sparsentan (SPAR) vs Irbesartan (IRB) in Patients With Focal Segmental Glomerulosclerosis (FSGS): Results From the Phase 3 DUPLEX Trial